# OnCo record fid-022 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/fid-022/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "fid-022" ;
  schema:name "FID-022"@en ;
  schema:description "FID-022 is an experimental nanoencapsulated SN38 and irinotecan, topoisomerase I chemotherapy from Fulgent Genetics, in phase 1 trials for advanced solid tumours."@en ;
  schema:url <https://onco.cc/drugs/fid-022/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/api/v2/studies/NCT06694480>, <https://www.sec.gov/Archives/edgar/data/1674930/000119312526326119/flgt-ex99_2.htm>, <https://clinicaltrials.gov/search?intr=FID-022> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Nanoencapsulated SN38 and irinotecan, topoisomerase I chemotherapy (polyethyloxazoline material)" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:companies <https://onco.cc/companies/fulgent-genetics/> ;
  onco:trials <https://onco.cc/trials/nct06694480/> .